Blue Jet Healthcare Limited (BLUEJET.NS) Stock Competitors & Peer Comparison
See (BLUEJET.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLUEJET.NS | ₹521.60 | +0.02% | 89.3B | 29.23 | ₹17.61 | +0.23% |
| BIOCON.BO | ₹427.35 | +1.42% | 578.9B | 150.12 | ₹2.82 | +0.12% |
| BIOCON.NS | ₹425.70 | +1.09% | 578.7B | 150.07 | ₹2.82 | +0.12% |
| ANTHEM.NS | ₹776.65 | +1.37% | 435.9B | 74.32 | ₹10.44 | N/A |
| ONESOURCE.NS | ₹1,558.80 | -3.47% | 179.7B | -243.83 | -₹6.43 | N/A |
| SYNGENE.BO | ₹439.80 | -0.82% | 175.2B | 55.55 | ₹7.85 | +0.29% |
| SYNGENE.NS | ₹438.85 | -1.03% | 175.2B | 55.26 | ₹7.89 | +0.29% |
| CONCORDBIO.NS | ₹1,319.70 | -1.34% | 137.9B | 53.31 | ₹24.72 | +0.81% |
| CONCORDBIO.BO | ₹1,325.25 | -1.09% | 137.9B | 53.20 | ₹24.79 | +0.81% |
| BLUEJET.BO | ₹521.00 | -0.06% | 89.3B | 36.07 | ₹14.27 | +0.23% |
Stock Comparison
BLUEJET.NS vs BIOCON.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, BIOCON.BO has a market cap of 578.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while BIOCON.BO trades at ₹427.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas BIOCON.BO's P/E ratio is 150.12. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, BLUEJET.NS is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check BIOCON.BO's competition here
BLUEJET.NS vs BIOCON.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, BIOCON.NS has a market cap of 578.7B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while BIOCON.NS trades at ₹425.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas BIOCON.NS's P/E ratio is 150.07. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, BLUEJET.NS is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check BIOCON.NS's competition here
BLUEJET.NS vs ANTHEM.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, ANTHEM.NS has a market cap of 435.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while ANTHEM.NS trades at ₹776.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas ANTHEM.NS's P/E ratio is 74.32. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to ANTHEM.NS's ROE of +0.22%. Regarding short-term risk, BLUEJET.NS is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check ANTHEM.NS's competition here
BLUEJET.NS vs ONESOURCE.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, ONESOURCE.NS has a market cap of 179.7B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while ONESOURCE.NS trades at ₹1,558.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas ONESOURCE.NS's P/E ratio is -243.83. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, BLUEJET.NS is more volatile compared to ONESOURCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check ONESOURCE.NS's competition here
BLUEJET.NS vs SYNGENE.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SYNGENE.BO has a market cap of 175.2B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SYNGENE.BO trades at ₹439.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SYNGENE.BO's P/E ratio is 55.55. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SYNGENE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SYNGENE.BO's competition here
BLUEJET.NS vs SYNGENE.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SYNGENE.NS has a market cap of 175.2B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SYNGENE.NS trades at ₹438.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SYNGENE.NS's P/E ratio is 55.26. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SYNGENE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SYNGENE.NS's competition here
BLUEJET.NS vs CONCORDBIO.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, CONCORDBIO.NS has a market cap of 137.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while CONCORDBIO.NS trades at ₹1,319.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas CONCORDBIO.NS's P/E ratio is 53.31. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, BLUEJET.NS is more volatile compared to CONCORDBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check CONCORDBIO.NS's competition here
BLUEJET.NS vs CONCORDBIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, CONCORDBIO.BO has a market cap of 137.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while CONCORDBIO.BO trades at ₹1,325.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas CONCORDBIO.BO's P/E ratio is 53.20. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, BLUEJET.NS is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check CONCORDBIO.BO's competition here
BLUEJET.NS vs BLUEJET.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, BLUEJET.BO has a market cap of 89.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while BLUEJET.BO trades at ₹521.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas BLUEJET.BO's P/E ratio is 36.07. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to BLUEJET.BO's ROE of +0.20%. Regarding short-term risk, BLUEJET.NS is more volatile compared to BLUEJET.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check BLUEJET.BO's competition here
BLUEJET.NS vs SUPRIYA.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SUPRIYA.NS has a market cap of 77.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SUPRIYA.NS trades at ₹973.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SUPRIYA.NS's P/E ratio is 37.00. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SUPRIYA.NS's competition here
BLUEJET.NS vs SUPRIYA.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SUPRIYA.BO has a market cap of 77.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SUPRIYA.BO trades at ₹976.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SUPRIYA.BO's P/E ratio is 36.94. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SUPRIYA.BO's competition here
BLUEJET.NS vs ZOTA.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, ZOTA.NS has a market cap of 41.7B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while ZOTA.NS trades at ₹1,393.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas ZOTA.NS's P/E ratio is -58.77. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, BLUEJET.NS is more volatile compared to ZOTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check ZOTA.NS's competition here
BLUEJET.NS vs PANACEABIO.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, PANACEABIO.NS has a market cap of 33.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while PANACEABIO.NS trades at ₹545.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas PANACEABIO.NS's P/E ratio is -643.26. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, BLUEJET.NS is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check PANACEABIO.NS's competition here
BLUEJET.NS vs PANACEABIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, PANACEABIO.BO has a market cap of 33.8B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while PANACEABIO.BO trades at ₹553.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas PANACEABIO.BO's P/E ratio is -642.44. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, BLUEJET.NS is more volatile compared to PANACEABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check PANACEABIO.BO's competition here
BLUEJET.NS vs DCAL.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, DCAL.NS has a market cap of 27.1B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while DCAL.NS trades at ₹173.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas DCAL.NS's P/E ratio is 27.82. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, BLUEJET.NS is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check DCAL.NS's competition here
BLUEJET.NS vs DCAL.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, DCAL.BO has a market cap of 27.1B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while DCAL.BO trades at ₹175.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas DCAL.BO's P/E ratio is 27.82. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, BLUEJET.NS is more volatile compared to DCAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check DCAL.BO's competition here
BLUEJET.NS vs TITANBIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, TITANBIO.BO has a market cap of 17.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while TITANBIO.BO trades at ₹422.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas TITANBIO.BO's P/E ratio is 57.61. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, BLUEJET.NS is more volatile compared to TITANBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check TITANBIO.BO's competition here
BLUEJET.NS vs 3BBLACKBIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, 3BBLACKBIO.BO has a market cap of 10.1B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while 3BBLACKBIO.BO trades at ₹1,181.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas 3BBLACKBIO.BO's P/E ratio is 16.87. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, BLUEJET.NS is more volatile compared to 3BBLACKBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check 3BBLACKBIO.BO's competition here
BLUEJET.NS vs FERMENTA.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, FERMENTA.BO has a market cap of 10.1B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while FERMENTA.BO trades at ₹369.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas FERMENTA.BO's P/E ratio is 14.35. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, BLUEJET.NS is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check FERMENTA.BO's competition here
BLUEJET.NS vs KILPEST.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, BLUEJET.NS is less volatile compared to KILPEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check KILPEST.BO's competition here
BLUEJET.NS vs TAKE.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, TAKE.NS has a market cap of 4.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while TAKE.NS trades at ₹29.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas TAKE.NS's P/E ratio is 102.31. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, BLUEJET.NS is less volatile compared to TAKE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check TAKE.NS's competition here
BLUEJET.NS vs TAKE.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, TAKE.BO has a market cap of 4.3B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while TAKE.BO trades at ₹29.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas TAKE.BO's P/E ratio is 103.21. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, BLUEJET.NS is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check TAKE.BO's competition here
BLUEJET.NS vs HALEOSLABS.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, HALEOSLABS.NS has a market cap of 4.2B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while HALEOSLABS.NS trades at ₹1,376.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas HALEOSLABS.NS's P/E ratio is 24.02. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, BLUEJET.NS is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check HALEOSLABS.NS's competition here
BLUEJET.NS vs SMSLIFE.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SMSLIFE.BO has a market cap of 4B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SMSLIFE.BO trades at ₹1,310.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SMSLIFE.BO's P/E ratio is 21.18. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SMSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SMSLIFE.BO's competition here
BLUEJET.NS vs HALEOSLABS.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, HALEOSLABS.BO has a market cap of 4B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while HALEOSLABS.BO trades at ₹1,310.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas HALEOSLABS.BO's P/E ratio is 22.90. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, BLUEJET.NS is less volatile compared to HALEOSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check HALEOSLABS.BO's competition here
BLUEJET.NS vs SMSLIFE.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, BLUEJET.NS is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check SMSLIFE.NS's competition here
BLUEJET.NS vs LYKALABS.NS Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, LYKALABS.NS has a market cap of 2.4B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while LYKALABS.NS trades at ₹68.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas LYKALABS.NS's P/E ratio is -23.87. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, BLUEJET.NS is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check LYKALABS.NS's competition here
BLUEJET.NS vs LYKALABS.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, LYKALABS.BO has a market cap of 2.4B. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while LYKALABS.BO trades at ₹67.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas LYKALABS.BO's P/E ratio is -28.96. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, BLUEJET.NS is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check LYKALABS.BO's competition here
BLUEJET.NS vs ALFAVIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, ALFAVIO.BO has a market cap of 274.6M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while ALFAVIO.BO trades at ₹8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas ALFAVIO.BO's P/E ratio is 217.75. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, BLUEJET.NS is less volatile compared to ALFAVIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check ALFAVIO.BO's competition here
BLUEJET.NS vs TRABI.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, TRABI.BO has a market cap of 223.5M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while TRABI.BO trades at ₹3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas TRABI.BO's P/E ratio is -13.41. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, BLUEJET.NS is more volatile compared to TRABI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check TRABI.BO's competition here
BLUEJET.NS vs VANTABIO.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, VANTABIO.BO has a market cap of 180.3M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while VANTABIO.BO trades at ₹25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas VANTABIO.BO's P/E ratio is 169.00. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to VANTABIO.BO's ROE of -0.17%. Regarding short-term risk, BLUEJET.NS is less volatile compared to VANTABIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check VANTABIO.BO's competition here
BLUEJET.NS vs SAMSRITA.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SAMSRITA.BO has a market cap of 171.8M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SAMSRITA.BO trades at ₹11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SAMSRITA.BO's P/E ratio is -8.59. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SAMSRITA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SAMSRITA.BO's competition here
BLUEJET.NS vs STARSOURCE.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, STARSOURCE.BO has a market cap of 144.4M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while STARSOURCE.BO trades at ₹96.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas STARSOURCE.BO's P/E ratio is -1.22. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, BLUEJET.NS is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check STARSOURCE.BO's competition here
BLUEJET.NS vs GVBL.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, GVBL.BO has a market cap of 107.2M. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while GVBL.BO trades at ₹35.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas GVBL.BO's P/E ratio is 351.10. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, BLUEJET.NS is more volatile compared to GVBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BLUEJET.NS.Check GVBL.BO's competition here
BLUEJET.NS vs SERVOTEACH.BO Comparison June 2026
BLUEJET.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUEJET.NS stands at 89.3B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, BLUEJET.NS is priced at ₹521.60, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUEJET.NS currently has a P/E ratio of 29.23, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, BLUEJET.NS's ROE is +0.20%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, BLUEJET.NS is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUEJET.NS.Check SERVOTEACH.BO's competition here